SCHEMBL221734

SCHEMBL221734

Cc1cccc(Cc2nc3ccccc3n2CC(=O)N2CCOCC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
CYP2C19 P33261 1/20 0.57
ALDH1A1 P00352 6/20 0.56
ALDH1A2 O94788 3/20 0.56
ALDH2 P05091 3/20 0.56
ALDH3A1 P30838 3/20 0.56
ALDH1A3 P47895 3/20 0.56
BRD4 O60885 1/20 0.56
CREBBP Q92793 1/20 0.56
TP53 P04637 4/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAPT P10636 5/20 0.54
GAA P10253 1/20 0.54
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GRIN2B Q13224 1/20 0.52
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17824298 0.74 CYP3A4 (0.66) CYP3A4CYP2C19ALDH1A1TP53MEN1
SCHEMBL221735 0.73 TP53 (0.47) ALDH1A1ALDH1A2ALDH2ALDH3A1ALDH1A3
SCHEMBL10196663 0.73 POLB (0.76) ALDH1A1TP53MEN1KMT2AMAPT
SCHEMBL8599093 0.72 MAPT (0.75) CYP3A4CYP2C19ALDH1A1TP53MEN1
SCHEMBL2607592 0.71 TP53 (0.56) CYP3A4CYP2C19ALDH1A1TP53MEN1
SCHEMBL13182216 0.69 KDM4E (0.67) CYP3A4CYP2C19ALDH1A1TP53MEN1
SCHEMBL15643258 0.69 APEX1 (0.71) CYP3A4CYP2C19ALDH1A1TP53MEN1
SCHEMBL18363182 0.68 GRIN2B (1.00) GRIN2B
SCHEMBL20989184 0.67 LMNA (0.53) TP53MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL14487436 0.67 APEX1 (0.60) CYP2C19ALDH1A1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin NEW AVON LLC (US) 2020-12-01 US disclosed
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin NEW AVON LLC (US) 2020-12-01 US disclosed
EP-3272329-B1 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PROD INC (US) 2020-09-16 EP disclosed
EP-3272329-B1 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PROD INC (US) 2020-09-16 EP disclosed
US-20180271772-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC 2018-09-27 US disclosed
US-9999587-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2018-06-19 US disclosed
US-9999587-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2018-06-19 US disclosed
US-9999587-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2018-06-19 US disclosed
EP-3272329-A2 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2018-01-24 EP disclosed
EP-3272329-A2 COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2018-01-24 EP disclosed
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin CITIBANK, N.A., LONDON BRANCH 2016-01-14 US disclosed
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin CITIBANK, N.A., LONDON BRANCH 2016-01-14 US disclosed
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin CITIBANK, N.A., LONDON BRANCH 2016-01-14 US disclosed
US-9132294-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2015-09-15 US disclosed
US-9132294-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin AVON PRODUCTS, INC. (US) 2015-09-15 US disclosed
EP-2588593-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN Avon Products, Inc. (US) 2013-05-08 EP disclosed
WO-2012005876-A2 COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN AVON PRODUCTS, INC. (US) 2012-01-12 WO disclosed
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC. (US) 2012-01-05 US disclosed
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin AVON PRODUCTS, INC. (US) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180271772-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA CYP3A4 4877/4885CYP2C19 4859/4885ALDH1A1 4291/4885
US-20160008266-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA CYP3A4 4877/4885CYP2C19 4859/4885ALDH1A1 4291/4885
US-10849840-B2 Compositions and methods for stimulation MAGP-1 to improve the appearance of skin MAG, MFAP1, CUTA CYP3A4 4877/4885CYP2C19 4859/4885ALDH1A1 4291/4885
US-20120003332-A1 Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin MAG, MFAP1, CUTA CYP3A4 4877/4885CYP2C19 4859/4885ALDH1A1 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.